In late 2011, a year after swine flu outbreaks in India, three vaccine manufacturers were contracted for nearly two million doses of H1N1 vaccine to the government. Serum Institute of India, Bharat Biotech and Panacea Biotec had obtained licenses for their products the previous year, invested in new plants and were all set to supply the doses. For the paediatric vaccine makers, this was the first big step towards adult vaccines and a whole new market. Today, those expired doses are dumped in warehouses. The plants lay idle as the companies await closure of an arbitration with the ministry of health.
Weapons of Mass Protection